Key result
Review outlines the intersection of oncological and cardiovascular diseases covering cardiac neoplasms and secondary effects.
Why the study?
The intersection of oncological and cardiovascular diseases is an increasingly recognized phenomenon, expanding cardio-oncology beyond primary cardiac tumors and chemotherapeutic complications to metastatic and secondary cardiovascular effects of neoplasia.
This review highlights the broad scope of cardio-oncology, encompassing primary and metastatic cardiac tumors as well as secondary cardiovascular complications of cancer and its treatments.
Broadens cardio-oncology to metastatic cardiac neoplasms; leaves open evidence-based management protocols.
The intersection of oncological and cardiovascular diseases is an increasingly recognized phenomenon. This recognition has led to the emergence of cardio-oncology as a true subspecialty. This field is not simply limited to primary cardiac tumors or complications of chemotherapeutic medications. Rather, it also encompasses metastatic cardiovascular complications and secondary cardiovascular effects of the underlying neoplasia. This review will broadly cover primary and metastatic cardiac neoplasms, as well as secondary cardiovascular effects of extracardiac neoplasia (e.g., amyloidosis, carcinoid valvulopathy, and chemotherapeutic cardiotoxicities).
No takes yet. Share an insight, caveat, or question.
Maleszewski et al. (2018) conducted a review in Oncological and cardiovascular diseases. This review highlights the intersection of oncological and cardiovascular diseases, covering primary and metastatic cardiac neoplasms and secondary cardiovascular effects of extracardiac neoplasia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: